UK real-world observational study of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results.

被引：0
|
作者：
Nathan, Paul D.
Charnley, Natalie
Frazer, Ricky
McGrane, John
Muazzam, Iqtedar A.
Rudman, Sarah
Sharma, Anand
Stevenson, Robert
Hickey, Joseph David
Tahim, Arpan
Ritchie, Aimi Rose
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Lancashire Teaching Hosp, Preston, Lancs, England
[3] Velindre Canc Ctr, Cardiff, Wales
[4] Royal Cornwall Hosp NHS Trust, Cornwall, England
[5] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England
[6] Guys & St Thomas NHS Fdn Trust, London, England
[7] Mt Vernon Canc Ctr, East & North Hertfordshire NHS Trust, Northwood, Middx, England
[8] Queen Elizabeth Hosp, Birmingham, W Midlands, England
[9] OPEN Hlth, Real World Evidence, Marlow, Bucks, England
[10] Pfizer Ltd, Tadworth, Surrey, England
[11] Pfizer Ltd, Tadworth, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
631
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Avelumab plus axitinib in advanced renal cell carcinoma (aRCC): 12-month interim results from a real-world observational study in the United Kingdom.
    Nathan, Paul D.
    Muazzam, Iqtedar Ahmed
    Frazer, Ricky
    Sharma, Anand
    Hickey, Joseph David
    Ritchie, Aimi Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] A UK real-world observational study of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.
    Nathan, Paul D.
    Charnley, Natalie
    Frazer, Ricky
    McGrane, John
    Muazzam, Iqtedar
    Pillai, Manon
    Rudman, Sarah
    Stevenson, Robert
    Venugopal, Balaji
    Hickey, Joseph David
    Ritchie, Aimi Rose
    Liu, Kin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 386 - 386
  • [3] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Haanen, John B. A. G.
    Larkin, James M. G.
    Uemura, Motohide
    Pal, Sumanta K.
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae-Lyun
    Ching, Keith A.
    Mu, Xinmeng Jasmine
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Campbell, Matthew T.
    Alekseev, Boris Y.
    Uemura, Motohide
    Kollmannsberger, Christian K.
    Gravis, Gwenaelle
    Bjarnason, Georg A.
    Gurney, Howard
    Chung, Jinsoo
    Haanen, John B. A. G.
    Rini, Brian I.
    Larkin, James M. G.
    Schmidinger, Manuela
    Nole, Franco
    Chudnovsky, Aleksander
    Huang, Bo
    Hariharan, Subramanian
    di Pietro, Alessandra
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Donahue, Amber C.
    Rini, Brian I.
    Powles, Thomas
    Haanen, John B. A. G.
    Larkin, James
    Mu, Xinmeng Jasmine
    Pu, Jie
    Thomaidou, Despina
    Di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
    Tsimafeyeu, Ilya
    Chubenko, Vyacheslav
    Baklanova, Olga
    Kalpinskiy, Alexey
    Safina, Sufia
    Lebedinets, Andrei
    Petkau, Vladislav
    Parsadanova, Elvira
    Turganova, Maria
    Shkurat, Aleksei
    Tovbik, Natalia
    Tkacheva, Elena
    Anzhiganova, Yulia
    Novikova, Olga
    Bragina, Varvara
    Zukov, Ruslan
    Orlova, Rashida
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [7] Avelumab plus axitinib for first-line treatment of advanced renal cell carcinoma: A real-world ambispective RAVE-Renal study.
    Chubenko, Viacheslav
    Baklanova, Olga
    Kalpinskiy, Alexey
    Safina, Sufiia
    Lebedinets, Andrey
    Shkurat, Alexey
    Parsadanova, Elvira
    Turganova, Maria
    Petkau, Vladislav
    Tovbik, Natalya
    Tkacheva, Elena
    Anzhiganova, Yulia
    Novikova, Olga
    Bragina, Varvara
    Zukov, Ruslan
    Tsimafeyeu, Ilya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 117 - 117
  • [8] Real-world effectiveness and safety of first-line (1L) avelumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.
    Merseburger, Axel Stuart
    Baklanova, Olga
    Garlonta, Victor T.
    Androulakis, Nikolaos E. M.
    Christopoulou, Athina
    Timotheadou, Eleni
    Demey, Wim
    Janssen, Jan
    Ivanyi, Philipp
    Brouwers, Barbara Anna Henk
    Wynendaele, Wim
    Wang, Lusha
    Kostkova, Lenka
    Hoffman, Jason
    Manzel, Arndt
    Koumarianou, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [9] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.
    Haanen, John B. A. G.
    Larkin, James
    Choueiri, Toni K.
    Albiges, Laurence
    Rini, Brian I.
    Atkins, Michael B.
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Efficacy and safety of avelumab plus axitinib (A plus Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Motzer, Robert J.
    Choueiri, Toni K.
    Rini, Brian I.
    Miyake, Hideaki
    Uemura, Hirotsugu
    Albiges, Laurence
    Fujii, Yosuke
    Umeyama, Yoshiko
    Wang Jing
    Mariani, Mariangela
    Schmidinger, Manuela
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345